Tadahiko Igarashi

916 total citations
45 papers, 577 citations indexed

About

Tadahiko Igarashi is a scholar working on Oncology, Pathology and Forensic Medicine and Hematology. According to data from OpenAlex, Tadahiko Igarashi has authored 45 papers receiving a total of 577 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 16 papers in Pathology and Forensic Medicine and 14 papers in Hematology. Recurrent topics in Tadahiko Igarashi's work include Lymphoma Diagnosis and Treatment (15 papers), Chronic Lymphocytic Leukemia Research (11 papers) and Chronic Myeloid Leukemia Treatments (9 papers). Tadahiko Igarashi is often cited by papers focused on Lymphoma Diagnosis and Treatment (15 papers), Chronic Lymphocytic Leukemia Research (11 papers) and Chronic Myeloid Leukemia Treatments (9 papers). Tadahiko Igarashi collaborates with scholars based in Japan, United States and United Kingdom. Tadahiko Igarashi's co-authors include Kuniaki Itoh, Hirofumi Fujii, Yasutsuna Sasaki, Tomoko Ohtsu, Hironobu Minami, Hisashi Wakita, Nagahiro Saijo, Masaru Kojima, Shigeo Nakamura and Takashi Kumagai and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

Tadahiko Igarashi

45 papers receiving 565 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tadahiko Igarashi Japan 14 296 143 131 127 107 45 577
Shilpa Paul United States 13 232 0.8× 294 2.1× 122 0.9× 180 1.4× 52 0.5× 41 670
Isabelle Genvresse Germany 12 157 0.5× 169 1.2× 107 0.8× 99 0.8× 104 1.0× 27 472
Saurabh Zanwar United States 11 225 0.8× 142 1.0× 187 1.4× 76 0.6× 69 0.6× 69 504
Pierre Brousset France 10 296 1.0× 130 0.9× 89 0.7× 85 0.7× 314 2.9× 23 582
Tahir Latif United States 13 214 0.7× 133 0.9× 211 1.6× 91 0.7× 93 0.9× 38 588
Filiz Şen United States 16 213 0.7× 117 0.8× 112 0.9× 163 1.3× 278 2.6× 42 623
Radovan Vrḫovac Croatia 15 253 0.9× 243 1.7× 223 1.7× 330 2.6× 227 2.1× 65 810
Eri Matsuki Japan 11 249 0.8× 153 1.1× 61 0.5× 127 1.0× 134 1.3× 41 492
Leopold Öhler Austria 13 200 0.7× 198 1.4× 101 0.8× 106 0.8× 35 0.3× 49 478
In Keun Choi South Korea 14 128 0.4× 98 0.7× 101 0.8× 79 0.6× 54 0.5× 36 420

Countries citing papers authored by Tadahiko Igarashi

Since Specialization
Citations

This map shows the geographic impact of Tadahiko Igarashi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tadahiko Igarashi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tadahiko Igarashi more than expected).

Fields of papers citing papers by Tadahiko Igarashi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tadahiko Igarashi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tadahiko Igarashi. The network helps show where Tadahiko Igarashi may publish in the future.

Co-authorship network of co-authors of Tadahiko Igarashi

This figure shows the co-authorship network connecting the top 25 collaborators of Tadahiko Igarashi. A scholar is included among the top collaborators of Tadahiko Igarashi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tadahiko Igarashi. Tadahiko Igarashi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yamaguchi, Hiroki, Naoki Takezako, Kazuteru Ohashi, et al.. (2020). Treatment-free remission after first-line dasatinib treatment in patients with chronic myeloid leukemia in the chronic phase: the D-NewS Study of the Kanto CML Study Group. International Journal of Hematology. 111(3). 401–408. 8 indexed citations
2.
Najima, Yuho, Chikashi Yoshida, Noriyoshi Iriyama, et al.. (2018). Regulatory T cell inhibition by dasatinib is associated with natural killer cell differentiation and a favorable molecular response—The final results of the D-first study. Leukemia Research. 66. 66–72. 29 indexed citations
3.
Matsue, Kosei, Kyoya Kumagai, Isamu Sugiura, et al.. (2018). Plerixafor for mobilization and collection of haematopoietic stem cells for autologous transplantation in Japanese patients with non-Hodgkin lymphoma: a randomized phase 2 study. International Journal of Hematology. 108(5). 524–534. 10 indexed citations
4.
Yoshida, Takeshi, et al.. (2017). The analysis of prognosis in aggressive lymphoma patients - importance of thrombocytopenia as a prognostic factor. Annals of Oncology. 28. ix108–ix108. 1 indexed citations
5.
6.
7.
Igarashi, Tadahiko, Michinori Ogura, Kuniaki Itoh, et al.. (2016). Japanese phase II study of rituximab maintenance for untreated indolent B-cell non-Hodgkin lymphoma with high tumor burden. International Journal of Hematology. 104(6). 700–708. 5 indexed citations
8.
9.
Kojima, Masaru, Naoya Nakamura, Kayoko Murayama, et al.. (2010). Reactive Lymphoid Hyperplasia with Giant Follicles Associated with a Posttherapeutic State of Hematological Malignancies. A Report of Eight Cases. Tumori Journal. 96(1). 143–148. 5 indexed citations
10.
Kojima, Masaru, Naoya Nakamura, Shinji Sakurai, et al.. (2010). Progressive transformation of the germinal center of extranodal organs: A clinicopathological, immunohistochemical, and genotypic study of 14 cases. Pathology - Research and Practice. 206(4). 235–240. 4 indexed citations
11.
Minami, Hironobu, Kenji Kawada, Yasutsuna Sasaki, et al.. (2009). Population pharmacokinetics of docetaxel in patients with hepatic dysfunction treated in an oncology practice. Cancer Science. 100(1). 144–149. 33 indexed citations
12.
13.
Ogura, Michinori, Yasuo Morishima, Yoshitoyo Kagami, et al.. (2006). Randomized phase II study of concurrent and sequential rituximab and CHOP chemotherapy in untreated indolent B‐cell lymphoma. Cancer Science. 97(4). 305–312. 23 indexed citations
14.
Ebi, Hiromichi, Toshiaki Saeki, Kenji Kawada, et al.. (2005). Pharmacokinetic and pharmacodynamic comparison of fluoropyrimidine derivatives, capecitabine and 5′-deoxy-5-fluorouridine (5′-DFUR). Cancer Chemotherapy and Pharmacology. 56(2). 205–211. 14 indexed citations
15.
Ebi, Hiromichi, Masanobu Nakata, Makoto Tahara, et al.. (2003). Extragonadal germ cell tumors in Japan. Cancer Science. 94(12). 1107–1111. 8 indexed citations
16.
Minami, Hironobu, Tomoko Ohtsu, Hirofumi Fujii, et al.. (2001). Phase I Study of Intravenous PSC‐833 and Doxorubicin: Reversal of Multidrug Resistance. Japanese Journal of Cancer Research. 92(2). 220–230. 10 indexed citations
17.
Miya, Toshimichi, Tomoyuki Goya, Hirofumi Fujii, et al.. (2001). Factors Affecting the Pharmacokinetics of CPT-11: The Body Mass Index, Age and Sex are Independent Predictors of Pharmacokinetic Parameters of CPT-11. Investigational New Drugs. 19(1). 61–67. 31 indexed citations
18.
Sekine, Ikuo, Yasutsuna Sasaki, Tomoko Ohtsu, et al.. (1996). Recurrent Breast Cancer Treated Successfully with Mitomycin-C and Vinblastine after Failure of Both Doxorubicin-containing Regimen and Paclitaxel-A Case Report.. The Tohoku Journal of Experimental Medicine. 178(3). 331–337. 2 indexed citations
19.
Yoshida, Yasushi, Hideo Hakusui, Hirofumi Fujii, et al.. (1995). Pharmacological Correlation between Total Drug Concentration and Lactones of CPT‐11 and SN‐38 in Patients Treated with CPT‐11. Japanese Journal of Cancer Research. 86(1). 111–116. 50 indexed citations
20.
Wakita, Hisashi, Takayoshi Asai, Akira Hirasawa, et al.. (1989). Treatment with gabexate mesilate for interstitial pneumonia after bone marrow transplantation.. Ensho. 9(6). 463–467. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shilpa Paul Breakdown of academic impact, for papers by Isabelle Genvresse Breakdown of academic impact, for papers by Saurabh Zanwar Breakdown of academic impact, for papers by Pierre Brousset Breakdown of academic impact, for papers by Tahir Latif Breakdown of academic impact, for papers by Filiz Şen Breakdown of academic impact, for papers by Radovan Vrḫovac Breakdown of academic impact, for papers by Eri Matsuki Breakdown of academic impact, for papers by Leopold Öhler Breakdown of academic impact, for papers by In Keun Choi
Rankless by CCL
2026